Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 30 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the launch of Rexigo™, an oral once-a-day pill for advanced prostate cancer patients in India. This therapy, which suppresses testosterone, is the first of its kind available in India, providing a more convenient alternative to injectable treatments. The launch aims to improve access and affordability for patients, as Rexigo™ is priced significantly lower than existing options.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 30, 2024, titled "Zydus Lifesciences launches Rexigo , the oral once-a-day pill for advanced prostate cancer patients in India".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases